Despite medical advancements, the late-stage diagnosis of HCC remains a major challenge, which underscores the need for more ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma ...

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Liver Cancer: Molecular Signaling Pathway of Tumor Development Decoded Apr. 23, 2024 — As a malignant disease of the liver cells, hepatocellular carcinoma (HCC) is one of the main causes of ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced ...

Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer, advances in MDS, TNBC, HCC, and perioperative lung cancer research to be ...

This was further validated in an HCC xenograft mouse model, where the combination of shCD39-CAR-T cells with mdivi-1 resulted ...